GSK PLC Sponsored ADR (GSK)
(Delayed Data from NYSE)
$43.55 USD
+0.54 (1.26%)
Updated Sep 16, 2024 04:00 PM ET
After-Market: $43.55 0.00 (0.00%) 4:56 PM ET
3-Hold of 5 3
A Value C Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$43.55 USD
+0.54 (1.26%)
Updated Sep 16, 2024 04:00 PM ET
After-Market: $43.55 0.00 (0.00%) 4:56 PM ET
3-Hold of 5 3
A Value C Growth A Momentum A VGM
Zacks News
Glaxo's Nucala Label Expansion Application Gets FDA Approval
by Zacks Equity Research
GlaxoSmithKline's (GSK) application to include treatment of eosinophilic granulomatosis with polyangiitis in Nucala's label was approved by the FDA.
Puma (PBYI) Stock Up More than 200% This Year: Here's Why
by Zacks Equity Research
Puma's (PBYI) shares skyrocket in the year so far on the approval of its cancer drug Nerlynx in the United States coupled with strategic collaborations.
3 Drug/Biotech Stocks in Focus on World AIDS Day
by Zacks Equity Research
On World AIDS Day, we look into some of the key pharma companies in the HIV market that are developing drugs to address the life threatening disease.
Gilead & 3 Other Drug Stocks in Focus this World AIDS Day
by Arpita Dutt
With 36.7 million people living with HIV, there remains significant need for new and improved drugs in this corner of the market that has players like Gilead (GILD).
Glaxo Begins Phase III Study on Injection to Prevent HIV
by Zacks Equity Research
Glaxo (GSK) announces start of a large late-stage African study on an experimental long-acting injection for the prevention of HIV.
Glaxo Stock Down So Far This Year: Is a Reversal in Store?
by Zacks Equity Research
Glaxo's shares have declined 7.9% this year so far.
Glaxo Submits NDA for Anti Relapse Malaria Medicine to FDA
by Zacks Equity Research
Glaxo (GSK) and partner Medicines for Malaria Venture filed a new drug application (NDA) with the FDA for single-dose anti relapse medicine for malaria.
Glaxo, Pfizer's ViiV Healthcare Begins HIV Drug Combo Study
by Zacks Equity Research
Glaxo (GSK) and partner Pfizer's ViiV Healthcare commences a phase III study on combo regimen of cabotegravir and rilpivirine for treatment of adults with virally suppressed HIV-1 infection.
J&J & Glaxo's Juluca Approval Puts Spotlight on HIV Space (Revised)
by Zacks Equity Research
As HIV and AIDS have limited medical cure but huge medical need, we see how different companies are trying to tap into this huge market.
Glaxo (GSK) Files for U.S. Label Expansion of COPD Inhaler
by Zacks Equity Research
Glaxo (GSK) and partner Innoviva submit a supplemental new drug application to the FDA for label expansion of its once-daily single inhaler triple therapy, Trelegy Ellipta.
J&J & Glaxo Get FDA Approval for First Two-Drug HIV Regimen
by Zacks Equity Research
J&J (JNJ) and Glaxo received FDA approval for Juluca, a two-drug complete regimen of Tivicay/rilpivirine and Edurant/dolutegravir as a single tablet for the treatment of HIV-1 infection.
Novartis (NVS) Receives EC Nod for Tasigna Label Expansion
by Zacks Equity Research
Novartis (NVS) oncology portfolio gets a boost with EC's approval for the label expansion of Tasigna for the treatment of pediatric patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia.
Theravance Shares Rise on Approval of Glaxo's COPD Therapy
by Zacks Equity Research
Theravance Biopharma's (TBPH) shares traded up as investors cheered the potential cash flows related to future sales of recently approved Glaxo's triple combination COPD therapy.
Glaxo's Triple Therapy COPD Inhaler Gets Marketing Nod in EU
by Zacks Equity Research
Glaxo (GSK) and partner Innoviva announced that their triple combination therapy, Trelegy Ellipta, was granted marketing authorization in the EU as maintenance therapy for the treatment of patients with COPD.
AstraZeneca's (AZN) Asthma Drug Benralizumab Approved by FDA
by Zacks Equity Research
AstraZeneca (AZN) received FDA approval for benralizumab for treating severe eosinophilic asthma.
Glaxo's Subcutaneous Formulation of Benlysta Approved in EU
by Zacks Equity Research
GlaxoSmithKline's (GSK) Benlysta receives approval for a new subcutaneous formulation in Europe as an add-on therapy for patients with SLE.
Mylan (MYL) Misses on Earnings and Sales Estimates in Q3
by Zacks Equity Research
Mylan (MYL) missed both earnings and sales estimates in the third quarter of 2017 as EpiPen sales continue to decline further.
Emergent (EBS) Q3 Earnings Beat Estimates, Guidance Raised
by Zacks Equity Research
Emergent's (EBS) earnings and revenues beat estimates in Q3. Revenues also rise year over year on higher product sales and increase in contract manufacturing revenues.
Novartis Buys French Radiopharmaceutical Company
by Zacks Equity Research
Novartis (NVS) plans to acquire France-based Advanced Accelerator Applications. The takeover will add RadioLigand Therapy, Lutathera, in its portfolio with potential to drive growth in the near term.
Foreign Stock Roundup: Novartis, Bayer, Glaxo, Total Beat on Earnings
by Swarup Gupta
Political developments guided the movement of most non U.S. markets this week.
Glaxo (GSK) Q3 Earnings Beat, Revenues In Line, Shares Down
by Zacks Equity Research
Glaxo's (GSK) Q3 earnings top estimates while revenues match the same. However, the bottom was flat at constant exchange rates (CER).
Glaxo (GSK) Q3 Earnings Surpass Estimates, Revenues In Line
by Zacks Equity Research
Glaxo's (GSK) Q3 earnings beat estimates, with revenues in line. Glaxo maintained its core 2017 earnings growth, with no Advair generics expected to be launched this year.
Drug/Biotech Stocks Q3 Earnings on Oct 25: AMGN, GSK, VRTX
by Zacks Equity Research
The pharma/biotech industry has seen a solid start to Q3 earnings as evident from J&J's encouraging results. Let's see if some of the other leading players - Amgen, Glaxo and Vertex - follow suit.
Should You Buy GlaxoSmithKline (GSK) Ahead of Earnings?
by Zacks Equity Research
GlaxoSmithKline (GSK) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Is Celgene (CELG) Poised for a Beat This Earnings Season?
by Zacks Equity Research
Celgene Corporation (CELG) is expected to beat estimates once again on the back of strong performance of key drug Revlimid.